Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,760
  • Shares Outstanding, K 31,375
  • Annual Sales, $ 90 K
  • Annual Income, $ -38,240 K
  • EBIT $ -37 M
  • EBITDA $ -37 M
  • 60-Month Beta -0.21
  • Price/Sales 345.13
  • Price/Cash Flow N/A
  • Price/Book 3.94

Options Overview Details

View History
  • Implied Volatility 224.31% (-20.26%)
  • Historical Volatility 59.39%
  • IV Percentile 39%
  • IV Rank 17.21%
  • IV High 1,130.39% on 12/03/25
  • IV Low 36.03% on 03/17/26
  • Expected Move (DTE 11) 1.1645 (106.83%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 91
  • Volume Avg (30-Day) 23
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 2,625
  • Open Int (30-Day) 2,561
  • Expected Range 0.0000 to 2.2545

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.22
  • Number of Estimates 1
  • High Estimate $-0.22
  • Low Estimate $-0.22
  • Prior Year $-0.51
  • Growth Rate Est. (year over year) +56.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9520 +13.45%
on 03/31/26
1.2300 -12.20%
on 03/11/26
-0.1200 (-10.00%)
since 03/06/26
3-Month
0.9520 +13.45%
on 03/31/26
1.4800 -27.03%
on 01/08/26
-0.3500 (-24.48%)
since 01/06/26
52-Week
0.9520 +13.45%
on 03/31/26
1.9454 -44.48%
on 06/10/25
-0.2100 (-16.28%)
since 04/04/25

Most Recent Stories

More News
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

NEW YORK , April 6, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced...

ATNM : 1.1100 (+13.22%)
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

ATNM : 1.1100 (+13.22%)
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

-       ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the...

ATNM : 1.1100 (+13.22%)
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical...

ATNM : 1.1100 (+13.22%)
The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 17, 2025) - Investorideas.com, a go-to investing platform covering biotech and pharma stocks issues a snapshot looking at the...

ATNM : 1.1100 (+13.22%)
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications

-  New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab

ATNM : 1.1100 (+13.22%)
Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies,...

ATNM : 1.1100 (+13.22%)
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

-  ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO ® ), second line therapy Dato-DXd (Trop-2 ADC DATROWAY...

ATNM : 1.1100 (+13.22%)
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology with continued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy,...

ATNM : 1.1100 (+13.22%)
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever...

ATNM : 1.1100 (+13.22%)

Business Summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended...

See More

Key Turning Points

3rd Resistance Point 1.0299
2nd Resistance Point 1.0199
1st Resistance Point 1.0002
Last Price 1.1100
1st Support Level 0.9705
2nd Support Level 0.9605
3rd Support Level 0.9408

See More

52-Week High 1.9454
Fibonacci 61.8% 1.5659
Fibonacci 50% 1.4487
Fibonacci 38.2% 1.3315
Last Price 1.1100
52-Week Low 0.9520

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.